Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07371156

PACE Versus PE for CPTSD (PACE Trial)

The objective of this pragmatic trial is to evaluate the beneficial and harmful effects of Patient-centred Modular Cognitive Behavioural Therapy (PACE) compared with the standard post-traumatic stress disorder (PTSD) treatment, Prolonged Exposure (PE), for adults with an ICD-11 diagnosis of Complex post-traumatic stress disorder (CPTSD).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Outpatient Clinic for PTSD, Department of Affective Disorders, Aarhus University Hospital Psychiatry, Aarhus, Denmark

Loading trial locations.

About this study

This trial is designed as an investigator-initiated, multi-centre, parallel group, randomised clinical superiority trial of PACE versus standard PTSD treatment, PE, for ICD-11 CPTSD. The total sample size will be 228 participants. The trial will take place at the Danish Veteran Centre and two clinics in the Mental Health Services in Denmark. The participants will be adult military veterans and psychiatric outpatients with ICD-11 CPTSD. After giving their consent, participants will be randomly assigned (1:1) to receive either PACE or PE.

The experimental intervention will be 26 hours PACE (delivered as 26 1-hour sessions of weekly individual psychotherapy). The control intervention will be 25.5 hours PE therapy (17 sessions of weekly individual psychotherapy delivered for 90-minutes).

Outcome assessors, data managers, statisticians, and conclusion drawers will be blinded to group allocation. The primary outcome will be clinician-rated ICD-11 CPTSD symptom severity assessed with the International Trauma Interview (ITI) at 9 months after randomisation. Secondary outcomes include serious adverse events, suicide attempts, symptoms of depression, stress, and anxiety, alcohol use problems, mental well-being, and functional impairment assessed at 9 months after randomisation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: ≥18 years.
  • Referred to PTSD treatment (which requires absence of severe psychiatric comorbidity dominating the clinical presentation, hindering trauma-focused psychotherapy, assessed by the referring clinician at point of referral (e.g. major depressive disorder, ADHD, autism spectrum disorders, personality disorders, psychotic disorders, alcohol- or substance use, and aggressive behaviours)).
  • Diagnosis of CPTSD according to ICD-11, assessed by the interviewing investigator using the ITI interview.
  • Written informed consent.

Exclusion criteria

  • Current self-harm or severe suicidality defined as at least one self-harm episode or one suicide-attempt the last three months, as assessed by the interviewing investigator.
  • Any other condition that markedly compromises the participant's ability to adhere to the treatment programme or follow-up, such IQ < 70 based on clinical judgement.
  • Currently involved in legal proceedings concerning work accident compensation related to PTSD, or trial regarding child custody.
  • Does not understand Danish or needs an interpreter.

Treatment and study plan

PACE

Other

26 hours PACE (delivered as 26 1-hour sessions of weekly individual psychotherapy).

PE

Other

25.5 hours PE therapy (17 sessions of weekly individual psychotherapy delivered for 90-minutes).

Primary outcomes

  1. ITI

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    CPTSD symptom severity assessed with the International Trauma Interview (ITI), (scale ranging from 0-48, higher scores indicate higher severity)

Secondary outcomes

  1. SAE

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Proportion of participants with at least one serious adverse event (SAE) during the intervention period, assessed via patient medical records by a blinded outcome adjudication committee. SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalisation or prolonging of existing hospitalisation, and resulted in persistent or significant disability or jeopardised the participant.

  2. Suicides and suicide attempts

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Proportion of participants with a suicide- or a suicide attempt during the intervention period, assessed via patient medical records by a blinded outcome adjudication committee.

  3. DASS-21, depression

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Symptoms of depression, assessed using the depression subscale from the Depression Anxiety Stress Scales-21 items (DASS-21), (scale ranging from 0-42, higher scores indicate higher severity of depression symptoms).

  4. DASS-21, anxiety

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Symptoms of anxiety, assessed using the anxiety subscale from the Depression Anxiety Stress Scales-21 items (DASS-21), (scale ranging from 0-42, higher scores indicate higher severity of anxiety symptoms).

  5. AUDIT

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Alcohol use problems, assessed using the Alcohol Use Disorders Identification Test (AUDIT), (scale from 0-40, higher scores indicate greater risk).

  6. WHO-5

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Mental well-being, assessed using the World Health Organization-Five Well-Being Index (WHO-5), (percentage score from 0-100, higher scores indicate better well-being).

  7. SDS

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Level of functioning, assessed using the Sheehan Disability Scale (SDS), (scale ranging from 0 (unimpaired) to 30 (highly impaired)).

Other outcomes

  1. ITQ

    Time frame: 3, 6, and 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Symptoms of ICD-11 complex PTSD, assessed with the International Trauma Questionnaire (ITQ), (a total symptom severity score will be calculated by summing PTDS items (P1-P6) and Disturbances in Self-Organization (items C1-C6) symptoms, yielding a score ranging from 0-48, with higher scores indicating greater CPTSD symptom severity)

  2. TIQ

    Time frame: 3, 6, and 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Trauma-related identity, assessed with the Trauma Identity Questionnaire, (scale ranging from 0 to 105 with higher scores representing presence of negative identity characteristics associated with traumatic experiences).

  3. ETMQ

    Time frame: 3, 6, and 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Sensory and cognitive-emotional qualities of traumatic memories, assessed with the Experiences of Traumatic Memories Questionnaire (ETMQ), (scores range from 0-32 with higher scores reflecting more intense sensation-based trauma memories).

  4. CSS

    Time frame: 3, 6, and 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Level of perceived social support, assessed with the Crisis Support Scale (CSS), (scale ranging from 6-42, higher scores indicate greater perceived social support).

  5. EQ-5D-5L

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Health-related quality of life, assessed using the European Quality of Life - 5 Dimensions, 5 Levels (EQ-5D-5L). Index score (score between -1 and 1, higher scores indicate better health).

  6. DSS

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Dissociative symptoms, assessed using the Dissociative Symptoms Scale (DSS), Scale ranging from 0 to 80, higher scores indicate greater dissociative symptom severity).

  7. MIOS

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Moral injury-related distress, assessed using the Moral Injury Outcome Scale (MIOS), (scale ranging from 0 to 56, higher scores indicate greater moral injury-related distress).

  8. ISI

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Insomnia severity, assessed using the Insomnia Severity Index (ISI), (scale ranging from 0 (no problem) to 28 (severe insomnia)).

  9. DASS-21, stress

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Symptoms of stress, assessed using the stress subscale from the Depression Anxiety Stress Scales-21 items (DASS-21), (scale ranging from 0-42, higher scores indicate higher severity of stress symptoms).

  10. DUDIT

    Time frame: End of intervention, 9 months after randomisation (and assessed as an exploratory outcome at 18 months after randomisation)

    Drug use problems, assessed using the Drug Use Disorders Identification Test (DUDIT), (scale from 0-44, higher scores indicate greater risk of drug-related disorders).

Study contacts

Contact information is provided by the study sponsor or research team.

Sofie Folke

CONTACT

[email protected]

+45 7216 3251

Sofie Folke

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Sofie Folke

Other Gov

Collaborators

  • Aarhus University Hospital
  • Copenhagen Trial Unit, Center for Clinical Intervention Research
  • Danish Veterans Centre
  • Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital

Registry information

Official study title

Patient-centred Modular Cognitive Behavioural Therapy Versus Prolonged Exposure Therapy for Complex Post-traumatic Stress Disorder: a Randomised Trial

Acronym: PACE

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jan 27, 2026
Registry last updated
Jun 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.